Annual CFO
-$111.62 M
-$115.17 M-3245.00%
December 31, 2023
Summary
- As of February 12, 2025, STRO annual cash flow from operations is -$111.62 million, with the most recent change of -$115.17 million (-3245.00%) on December 31, 2023.
- During the last 3 years, STRO annual CFO has fallen by -$43.81 million (-64.62%).
- STRO annual CFO is now -980.04% below its all-time high of $12.68 million, reached on December 31, 2018.
Performance
STRO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$64.52 M
-$73.97 M-782.35%
September 30, 2024
Summary
- As of February 12, 2025, STRO quarterly cash flow from operations is -$64.52 million, with the most recent change of -$73.97 million (-782.35%) on September 30, 2024.
- Over the past year, STRO quarterly CFO has dropped by -$78.59 million (-558.47%).
- STRO quarterly CFO is now -197.97% below its all-time high of $65.85 million, reached on September 30, 2022.
Performance
STRO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$105.73 M
-$31.01 M-41.51%
September 30, 2024
Summary
- As of February 12, 2025, STRO TTM cash flow from operations is -$105.73 million, with the most recent change of -$31.01 million (-41.51%) on September 30, 2024.
- Over the past year, STRO TTM CFO has increased by +$5.89 million (+5.27%).
- STRO TTM CFO is now -667.89% below its all-time high of $18.62 million, reached on September 30, 2018.
Performance
STRO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
STRO Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3245.0% | -558.5% | +5.3% |
| 3 y3 years | -64.6% | -558.5% | +5.3% |
| 5 y5 years | -980.0% | -558.5% | +5.3% |
STRO Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -3245.0% | at low | -198.0% | +0.3% | -1912.6% | +29.3% |
| 5 y | 5-year | -3245.0% | at low | -198.0% | +0.3% | -1912.6% | +29.3% |
| alltime | all time | -980.0% | at low | -198.0% | +0.3% | -667.9% | +29.3% |
Sutro Biopharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$64.52 M(-782.3%) | -$105.73 M(+41.5%) |
| Jun 2024 | - | $9.46 M(-114.6%) | -$74.72 M(-35.2%) |
| Mar 2024 | - | -$64.74 M(-560.1%) | -$115.37 M(+3.4%) |
| Dec 2023 | -$111.62 M(-3245.0%) | $14.07 M(-142.0%) | -$111.62 M(-25.4%) |
| Sep 2023 | - | -$33.50 M(+7.4%) | -$149.55 M(+197.9%) |
| Jun 2023 | - | -$31.20 M(-48.9%) | -$50.20 M(+126.2%) |
| Mar 2023 | - | -$60.99 M(+155.6%) | -$22.19 M(-725.2%) |
| Dec 2022 | $3.55 M(-104.3%) | -$23.86 M(-136.2%) | $3.55 M(-39.2%) |
| Sep 2022 | - | $65.85 M(-2167.0%) | $5.83 M(-106.9%) |
| Jun 2022 | - | -$3.19 M(-91.0%) | -$84.43 M(-2.4%) |
| Mar 2022 | - | -$35.26 M(+63.4%) | -$86.50 M(+5.9%) |
| Dec 2021 | -$81.68 M | -$21.58 M(-11.6%) | -$81.68 M(+3.4%) |
| Sep 2021 | - | -$24.41 M(+363.7%) | -$78.98 M(+9.3%) |
| Jun 2021 | - | -$5.26 M(-82.7%) | -$72.26 M(-9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$30.43 M(+61.2%) | -$79.50 M(+17.3%) |
| Dec 2020 | -$67.80 M(+4.3%) | -$18.88 M(+6.7%) | -$67.80 M(+9.2%) |
| Sep 2020 | - | -$17.69 M(+41.5%) | -$62.08 M(+2.6%) |
| Jun 2020 | - | -$12.50 M(-33.3%) | -$60.51 M(-4.9%) |
| Mar 2020 | - | -$18.73 M(+42.4%) | -$63.61 M(-2.2%) |
| Dec 2019 | -$65.02 M(-612.7%) | -$13.16 M(-18.4%) | -$65.02 M(+12.5%) |
| Sep 2019 | - | -$16.12 M(+3.3%) | -$57.80 M(-1081.0%) |
| Jun 2019 | - | -$15.60 M(-22.6%) | $5.89 M(-21.9%) |
| Mar 2019 | - | -$20.14 M(+239.4%) | $7.55 M(-40.5%) |
| Dec 2018 | $12.68 M(-134.2%) | -$5.93 M(-112.5%) | $12.68 M(-31.9%) |
| Sep 2018 | - | $47.57 M(-441.1%) | $18.62 M(-164.3%) |
| Jun 2018 | - | -$13.95 M(-7.1%) | -$28.95 M(+92.9%) |
| Mar 2018 | - | -$15.01 M | -$15.01 M |
| Dec 2017 | -$37.07 M(+181.9%) | - | - |
| Dec 2016 | -$13.15 M | - | - |
FAQ
- What is Sutro Biopharma annual cash flow from operations?
- What is the all time high annual CFO for Sutro Biopharma?
- What is Sutro Biopharma annual CFO year-on-year change?
- What is Sutro Biopharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sutro Biopharma?
- What is Sutro Biopharma quarterly CFO year-on-year change?
- What is Sutro Biopharma TTM cash flow from operations?
- What is the all time high TTM CFO for Sutro Biopharma?
- What is Sutro Biopharma TTM CFO year-on-year change?
What is Sutro Biopharma annual cash flow from operations?
The current annual CFO of STRO is -$111.62 M
What is the all time high annual CFO for Sutro Biopharma?
Sutro Biopharma all-time high annual cash flow from operations is $12.68 M
What is Sutro Biopharma annual CFO year-on-year change?
Over the past year, STRO annual cash flow from operations has changed by -$115.17 M (-3245.00%)
What is Sutro Biopharma quarterly cash flow from operations?
The current quarterly CFO of STRO is -$64.52 M
What is the all time high quarterly CFO for Sutro Biopharma?
Sutro Biopharma all-time high quarterly cash flow from operations is $65.85 M
What is Sutro Biopharma quarterly CFO year-on-year change?
Over the past year, STRO quarterly cash flow from operations has changed by -$78.59 M (-558.47%)
What is Sutro Biopharma TTM cash flow from operations?
The current TTM CFO of STRO is -$105.73 M
What is the all time high TTM CFO for Sutro Biopharma?
Sutro Biopharma all-time high TTM cash flow from operations is $18.62 M
What is Sutro Biopharma TTM CFO year-on-year change?
Over the past year, STRO TTM cash flow from operations has changed by +$5.89 M (+5.27%)